Navigation Links
New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia
Date:12/17/2007

are trying to harm them. As a result, they may become socially withdrawn, fearful, and agitated (2).

Schering-Plough acquired asenapine through its combination with Organon BioSciences on November 19, 2007.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential market for asenapine. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainti
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...Newswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: ...nd Chief Executive Officer, and Greg Browne, Chief...l Piper Jaffray Health Care Conference in New York...The conference session and webcast will be audio o... Jaffray will host a webcast of the presentation l...
(Date:11/20/2009)...ov. 20 BD (Becton, Dicki...he completion of its acquisition of HandyLab, Inc....ps and manufactures molecular diagnostic assays an...HandyLab announced an exclusive agreement for BD t...e HandyLab Jaguar(TM) platform, the first fully in...
(Date:11/20/2009)... 20 Soligenix, Inc. (OTC... formerly known as DOR BioPharma, Inc., a late-sta...has formed a consortium to develop thermostable te...ting vaccines. Soligenix received a $9.4 million g...fectious Diseases (NIAID), a division of the Natio...
Breaking Medicine Technology:Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6Unifi Med 5 0 Complete EMR and Practice Management Solution 5426 1Unifi Med 5 0 Complete EMR and Practice Management Solution 5426 2U S Patent Issued for Champions Biotechnologys Lead Oncology Drug 5424 1U S Patent Issued for Champions Biotechnologys Lead Oncology Drug 5424 2U S Patent Issued for Champions Biotechnologys Lead Oncology Drug 5424 3Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast 5422 1Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast 5422 2
...y to Submit a Supplemental New Drug Application to...April 6 Cephalon, Inc . (Nasdaq: CEPH ) today ...ical trial of NUVIGIL(R) (armodafinil) Tablets [C-...ated with jet lag disorder. Based on these findin...Application with the U.S. Food and Drug Administra...
...CORE Phase II Testing Certification with Edifecs C...es that are now required in X12 Version 5010 , , ...y that it will, together with its partners CAQH an...s and lessons learned from the CORE Phase II Certi...andated 5010 Rules, in a presentation at the HIMSS...
Other Medicine Technology:Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 2Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 3Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 4Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 2Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 3Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 4Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 5
(Date:11/21/2009)...NH based medical credentialing software company In...rm a partnerhsip with Amerinet, Inc., the leading ...ll help to transform quality care within the healt...ovember 21, 2009 -- ISG Group, LLC, doing business...nt with Amerinet Inc., a leading national healthca...
(Date:11/21/2009)...New Haven Dental Group merges their practice with ... , (PRWEB) November 21, 20...tners Dr. David Gibson, Dr. Dean Cloutier, Dr. Joh...ed their growing practice with that of esteemed co...n decided he wanted to retire from dentistry in or...
(Date:11/20/2009)...ov. 20 The American Ac... health care reform legislation released this week...nsurance individual coverage mandate. The actuarie...ill minimize adverse selection stemming from more ...he bill. ,, "The individual mandate language sh...
(Date:11/20/2009)...., Nov. 20 Rates of infe...aked in late October, but the pandemic flu virus c...l age groups, including the elderly, according to ...SE: DGX ), the world,s leading provider of diagn... its most recent Quest Diagnostics Health Trends(T...
(Date:11/20/2009)...N.C., Nov. 20 Samuel Gl...define what it means to be "happy" during the holi...specialty in family counseling and chair of the De...Gladding says research shows that it is the pressu...n depression during the holidays. ,, That,s why...
Breaking Medicine News(10 mins):Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:New Haven Dental Group Expands Their Vision 2Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Why Holidays Don't Have To Be 'Happy' 2
...from Company, INDIANAPOLIS, May 28 WellPoint, In...ts Operations, Technology and,Government Services ...ent,and chief executive officer of that organizati...eer, senior vice president of Enterprise,Solutions...
... S&R Communications Group announced,Friday that th... gas card,to one lucky employee each day for the r... A Lot, was created by the S&R upper management in...f," said Paul Dreyer,President. "We offer help to ...
...ome of these procedures may just be matter of conv...ews) -- Premature births of single babies in the U..., and a new report finds that Caesarean sections a.... Alan Fleischman, medical director and senior vic...
...shed in the May 2008 (volume 8, issue 25) edition ...nol (pic-noj-en-all), an antioxidant plant extract...educes blood sugar in type II diabetes patients, ...y of Arizona, Tucson, indicates Pycnogenol may ser...
...ears, Earth observing satellites have delivered va...tter understanding and improved management of the ...are increasing daily as decision-makers are faced ...o address these needs, ESA, the German Space Agenc...
...ponding to the decline in NeoStem,Inc.,s (Amex: N...ading days,Robin Smith, CEO, NeoStem said, "We kno...ould lead to the sudden decline in our share price...ategic investment from the New England Cryogenic C...
Other Medicine News:Health News:WellPoint Announces Realignment of Operations, Technology and Government Services Unit 2Health News:C-Sections Explain Jump in U.S. Preemie Births 2Health News:C-Sections Explain Jump in U.S. Preemie Births 3Health News:Study shows pine bark naturally reduces cardiovascular risk factors in diabetics 2Health News:Study shows pine bark naturally reduces cardiovascular risk factors in diabetics 3Health News:European conference addresses increasing demand for EO data 2Health News:NeoStem, Inc. Comments on Recent Selling Pressure 2
... American standard, corrected curve trial lenses a...ed in Marco refractors and are invaluable in treat...ets of other manufacturers contain a disproportion...which are less expensive to produce, and fewer len...
Marco LM-990A
LM-770 Digital Projection Lensemeter
EPIC
Medicine Products: